Biotech hiring goes global
Layoffs at major biotech hubs are nudging life‑science talent toward more global and distributed work models, with rising demand reported in countries like Britain, Canada and Switzerland. Observers say specialised technical skills travel, but that geographic flexibility can come with less job stability tied to market cycles. (biospace.com) (layoff.today)
Biotech layoffs are pushing more scientists and drug developers to look for jobs across borders instead of waiting for the next opening in Boston or San Diego. (biospace.com) BioSpace reported on April 15 that recruiters are seeing a more “borderless” market for specialized life-science workers as cuts in major United States hubs send candidates toward Britain, Canada and Switzerland. The same outlet said layoffs eased in the first quarter of 2026 from late 2025 levels, but total job cuts still ran above the first quarter of 2025 because of one large restructuring. (biospace.com 1) (biospace.com 2) The jobs traveling best are the narrow, expensive skills that companies struggle to replace: cell and gene therapy manufacturing, regulatory affairs, bioinformatics and clinical operations. British recruiters and job boards are still advertising demand in those areas even as employers stay cautious on overall headcount. (biotechnologyjobs.co.uk) (pharmiweb.jobs) Britain, Canada and Switzerland each have policy reasons to keep hiring. The British government’s Life Sciences Sector Plan, published July 16, 2025, calls the industry a national asset, while Canada is still funding its biomanufacturing and life sciences strategy and Switzerland’s biotech trade group says the sector drew CHF 2.5 billion in capital in 2024. (gov.uk) (ised-isde.canada.ca) (swissbiotech.org) Canada is also advertising itself as easier to hire into from abroad. BIOTECanada points employers to the Global Talent Stream for expedited access to foreign workers, and federal planning documents say the strategy includes a $49 million contribution to Aspect Biosystems for a clinical biomanufacturing project. (biotech.ca) (publications.gc.ca) Switzerland is selling a different mix: scale, exports and concentration. The Swiss Biotech Report says chemical, pharmaceutical and life-science products made up CHF 149 billion of Swiss exports in 2024, or 52 percent of the national total, giving employers around Basel and Zurich a deep base for research, manufacturing and regulatory jobs. (swissbiotech.org) Britain is making a similar pitch on scale. Government and industry figures put the United Kingdom life-sciences workforce at more than 300,000 jobs, with most of them outside London and the Southeast, which gives laid-off workers more than one regional market to target. (gov.uk) (abpi.org.uk) The shift does not mean biotech has become stable work. Recruiters told BioSpace that companies are still hiring selectively, and industry hiring reports describe a “targeted rather than expansive” market shaped by funding cycles, restructurings and program cuts. (biospace.com) (pharmiweb.jobs) For workers, that leaves a new map but not a calmer one: fewer careers tied to one lab cluster, and more roles tied to whichever country is funding the next factory, trial or platform. (biospace.com) (gov.uk) (ised-isde.canada.ca)
